Navigation Links
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association

Interim Data from Phase 1 Clinical Trial of SNS-595 in Acute Leukemia Demonstrates Additional Clinical Activity

SOUTH SAN FRANCISCO, Calif., June 11, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presented positive data from clinical studies of two of the company's anti-cancer product candidates, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association (EHA) in Vienna, Austria.

Interim Results from Sunesis' Phase 1 Study of SNS-595 in Acute Leukemias

Interim data from the company's ongoing Phase 1 clinical trial of SNS-595 in patients with relapsed and/or refractory acute leukemias continue to demonstrate SNS-595's anti-cancer activity when administered on either a weekly or twice-weekly schedule. To date, on the weekly schedule, five out of ten patients in the 50 mg/m2 and 60 mg/m2 dose cohorts experienced bone marrow blast reductions of more than 95 percent, including one complete remission with incomplete platelet recovery (CRp), one complete remission in a patient who demonstrated partial but incomplete recovery of normal hematopoietic blood elements (CRi) and one partial response (PR). Additionally, in the twice-weekly 40 mg/m2 dose cohort, one of three patients had blast reduction of more than 95 percent and that patient achieved a complete remission (CR). Several patients have gone on to receive and tolerate multiple courses of treatment with SNS-595.

The data presented from the Phase 1 clinical trial of SNS-595 show a correlation between plasma drug levels, modulation of a pharmacodynamic marker of biologic activity and clinical responses when treated with SNS-595. There is emerging evidence that clinical responses are observed when plasma concentrations of SNS-595 exceed and remain above a threshold level for approximately 20 hours per week of active treatment. The CR, CRp and CRi responses observed to date all had sustained blood levels above
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:8/20/2014)...   Ventana Medical Systems, Inc.  (Ventana), a ... its VENTANA System for Primary Diagnosis 1 ... for routine pathology, including primary diagnosis with human ... software coupled with either the VENTANA iScan Coreo ... automated digital slide creation, case management and computer ...
(Date:8/20/2014)... LAKE CITY , Aug. 20, 2014 ... revolutionary mobile diagnostic platform during a special event at ... Utah , on September 5, 2014. The event, ... LiveStreamed on the ApolloDx website, www.apollodx.com .    ... transform diagnostic testing," said Jared Bauer , Co-Founder ...
(Date:8/20/2014)... , Aug. 20, 2014 Trovagene, Inc. ... announced today that results from two clinical studies will ... for the Company,s urine-based diagnostic test for the detection ... IPV conference is scheduled to take place in ... to 25 th . Additionally, a new U.S. patent ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... HeartWare International, Inc. (NASDAQ: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to present at the Lazard Capital ... p.m. ET on Thursday, September 22, 2011.  The one-day ...
... and SEATTLE, Sept. 19, 2011 Varian ... Calypso Medical Technologies, Inc., today announced they have signed ... a privately-owned, Seattle-based developer and supplier of specialized products ... during radiosurgery and radiotherapy.  The acquisition, which is anticipated ...
Cached Medicine Technology:HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day 2Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 2Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 3Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 4Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 5
(Date:8/20/2014)... Missouri federal judge has remanded a lawsuit filed by a ... NaturaLyte to the City of St. Louis Circuit Court, reports ... rejected an assertion by the defendants that the plaintiffs’ claims ... v. Fresenius Medical Care North America Inc., et al., No. ... of the dialysis products GranuFlo and NaturaLyte. In 2012, the ...
(Date:8/20/2014)... News) -- Leaving the car at home and getting to ... your health, a new study indicates. Researchers looked at ... 76 percent of men and 72 percent of women drove ... women used public transit, and 14 percent of men and ... drove to work weighed more and had higher levels of ...
(Date:8/20/2014)... The Workgroup for Electronic Data Interchange ... use of health IT to create efficiencies in ... its annual fall conference, WEDI-Con 2014: The Next ... take place at the HYATT Regency in Reston, ... cross-section of payers, providers, government regulators, industry vendors ...
(Date:8/20/2014)... WI (PRWEB) August 20, 2014 Parents ... While the transition from summer months means buying textbooks ... element that is often a forgotten part of the ... , According to the American Psychological Association, 27% of ... year. Nearly half (45%) say they are stressed by ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Verndale is ... Inc. 500|5000 list; an exclusive list ranking the fastest-growing ... are ranked according to their yearly percentage revenue growth ... 8th time on the Inc. 5000 list where it ... Company, Verndale offers its clients a wide range of ...
Breaking Medicine News(10 mins):Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Want to Stay Slim? Leave the Car at Home 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2
... Simple exercise routines can improve lung function and overall fitness ... a small new study suggest. Cystic fibrosis, or CF, ... mucus in the lungs, resulting in frequent lung infections, breathing ... regimens are difficult to adhere to long-term, so a team ...
... at The Scripps Research Institute have found a temperature-sensing protein within ... activate an immune response. This process can occur as temperature rises, ... immune cells are "called" from the body,s warm interior to a ... online ahead of print by Nature Chemical Biology , is ...
... FRIDAY, May 6 (HealthDay News) -- Nail salon workers may ... a new study warns. Researchers recruited 80 Vietnamese women ... their work-related exposure to toluene, ethyl acetate and isopropyl acetate. ... Journal of Public Health , showed that the workers were ...
... bacteria associated with exposure to livestock was recently discovered ... contact with livestock, according to University of Iowa researchers. ... study of Staphylococcus aureus in child day care facilities ... in the UI College of Public Health, for her ...
... Reinberg HealthDay Reporter , THURSDAY, May ... antibiotics can often cure appendicitis, surgery remains the ... appendicitis may be treated with antibiotics alone, but ... surgery, and it is difficult to discern between ...
... May 6 (HealthDay News) -- Americans walked and biked a ... new research finds. But the increases were minor, especially ... in the American Journal of Public Health . ... 2009 U.S. National Household Travel Surveys and found that the ...
Cached Medicine News:Health News:Everyday Exercise Can Help Kids With Cystic Fibrosis: Study 2Health News:Scripps Research scientists show how shifts in temperature prime immune response 2Health News:Scripps Research scientists show how shifts in temperature prime immune response 3Health News:Study finds livestock-related 'Staph' strain in child care worker 2Health News:Surgery May Beat Antibiotics for Appendicitis, Study Finds 2Health News:Surgery May Beat Antibiotics for Appendicitis, Study Finds 3Health News:Americans Walking, Biking a Bit More, Research Shows 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: